{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:24:14Z","timestamp":1790792654998,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100005614","name":"Biogen (US)","doi-asserted-by":"publisher","award":["Study 101-MS-401"],"award-info":[{"award-number":["Study 101-MS-401"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0674-4","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T01:37:19Z","timestamp":1472002639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: a global, observational, follow-up study"],"prefix":"10.1186","volume":"16","author":[{"given":"Susan","family":"Friend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Richman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Bloomgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda M.","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mad\u00e9","family":"Wenten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,24]]},"reference":[{"key":"674_CR1","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1471-2377-13-58","volume":"13","author":"E Alcalde-Cabero","year":"2013","unstructured":"Alcalde-Cabero E, Almaz\u00e1n-Isla J, Garc\u00eda-Merino A, de S\u00e1 J, de Pedro-Cuesta J. Incidence of multiple sclerosis among European Economic Area populations, 1985-2009: the framework for monitoring. BMC Neurol. 2013;13:58.","journal-title":"BMC Neurol"},{"key":"674_CR2","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/01.grf.0000153881.20014.86","volume":"48","author":"KA Bennett","year":"2005","unstructured":"Bennett KA. Pregnancy and multiple sclerosis. Clin Obstet Gynecol. 2005;48:38\u201347.","journal-title":"Clin Obstet Gynecol"},{"key":"674_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1352458511417479","volume":"18","author":"M Cossburn","year":"2012","unstructured":"Cossburn M, Ingram G, Hirst C, Ben-Shlomo Y, Pickersgill TP, Robertson NP. Age at onset as a determinant of presenting phenotype and initial relapse recovery in multiple sclerosis. Mult Scler. 2012;18:45\u201354.","journal-title":"Mult Scler"},{"key":"674_CR4","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1053\/j.gastro.2011.01.055","volume":"140","author":"J Cosnes","year":"2011","unstructured":"Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785\u201394.","journal-title":"Gastroenterology"},{"key":"674_CR5","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1191\/1352458504ms1083oa","volume":"10","author":"PK Coyle","year":"2004","unstructured":"Coyle PK, Christie S, Fodor P, Fuchs K, Giesser B, Gutierrez A, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582\u20138.","journal-title":"Mult Scler"},{"key":"674_CR6","unstructured":"Biogen. Tysabri (natalizumab) injection, for intravenous use US prescribing information. 2015. http:\/\/www.tysabri.com\/prescribingInfo . Accessed 16 June 2015."},{"key":"674_CR7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamaneurol.2013.598","volume":"70","author":"R Rudick","year":"2013","unstructured":"Rudick R, Polman C, Clifford D, Miller D, Steinman L. Natalizumab: bench to bedside and beyond. JAMA Neurol. 2013;70:172\u201382.","journal-title":"JAMA Neurol"},{"key":"674_CR8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","volume":"356","author":"TA Yednock","year":"1992","unstructured":"Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature. 1992;356:63\u20136.","journal-title":"Nature"},{"key":"674_CR9","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa043335","volume":"353","author":"WJ Sandborn","year":"2005","unstructured":"Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2005;353:1912\u201325.","journal-title":"N Engl J Med"},{"key":"674_CR10","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"674_CR11","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","volume":"354","author":"RA Rudick","year":"2006","unstructured":"Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911\u201323.","journal-title":"N Engl J Med"},{"key":"674_CR12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Oneda S, Clarke J. Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:117\u201330.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"674_CR13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.20191","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Skov M, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009;86:108\u201316.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"674_CR14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.20193","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Osterburg I, Fuchs A, Buse E, Clarke J. Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitor. Birth Defects Res B Dev Reprod Toxicol. 2009;86:144\u201356.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"674_CR15","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1007\/s00415-012-6653-9","volume":"260","author":"MK Houtchens","year":"2013","unstructured":"Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202\u201314.","journal-title":"J Neurol"},{"key":"674_CR16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/bdrb.20189","volume":"86","author":"NG Wehner","year":"2009","unstructured":"Wehner NG, Shopp G, Rocca MS, Clarke J. Effects of natalizumab, an alpha4 integrin inhibitor, on the development of Hartley guinea pigs. Birth Defects Res B Dev Reprod Toxicol. 2009;86:98\u2013107.","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"674_CR17","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458511401944","volume":"17","author":"K Hellwig","year":"2011","unstructured":"Hellwig K, Haghikia A, Gold R. Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment. Mult Scler. 2011;17:958\u201363.","journal-title":"Mult Scler"},{"key":"674_CR18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0404.2010.01426.x","volume":"123","author":"IA Hoevenaren","year":"2011","unstructured":"Hoevenaren IA, de Vries LC, Rijnders RJ, Lotgering FK. Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases. Acta Neurol Scand. 2011;123:430\u20133.","journal-title":"Acta Neurol Scand"},{"key":"674_CR19","first-page":"S455","volume":"17","author":"A Mattioda","year":"2011","unstructured":"Mattioda A, Masera S, Romagnolo A, Matta M, Superti G, Caligiana L, et al. Healthy baby delivery after conception during natalizumab exposure: a case report [abstract]. Mult Scler. 2011;17:S455\u2013S6.","journal-title":"Mult Scler"},{"key":"674_CR20","first-page":"S227","volume":"17","author":"R Totaro","year":"2011","unstructured":"Totaro R, Rossi M, Casalena A, Carolei A. Pregnancy, delivery, and birth outcome after natalizumab use for multiple sclerosis: a report of two cases [abstract]. Mult Scler. 2011;17:S227\u2013S8.","journal-title":"Mult Scler"},{"key":"674_CR21","unstructured":"Committee for Medicinal Products for Human Use. Guideline on the exposure to medicinal products during pregnancy: need for post-authorisation data. . 2005. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Regulatory_and_procedural_guideline\/2009\/11\/WC500011303.pdf . Accessed 21 Nov 2014."},{"key":"674_CR22","unstructured":"US Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. 2002. http:\/\/www.fda.gov\/downloads\/ScienceResearch\/SpecialTopics\/WomensHealthResearch\/UCM133332.pdf . Accessed 7 Nov 2014."},{"key":"674_CR23","unstructured":"US Food and Drug Administration. Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment. 2005. http:\/\/www.fda.gov\/downloads\/RegulatoryInformation\/Guidances\/UCM126834.pdf . Accessed 30 Apr 2015."},{"key":"674_CR24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/bdra.10111","volume":"67","author":"A Correa-Villase\u00f1or","year":"2003","unstructured":"Correa-Villase\u00f1or A, Cragan J, Kucik J, O\u2019Leary L, Siffel C, Williams L. The Metropolitan Atlanta Congenital Defects Program: 35 years of birth defects surveillance at the Centers for Disease Control and Prevention. Birth Defects Res A Clin Mol Teratol. 2003;67:617\u201324.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"674_CR25","first-page":"65","volume":"79","author":"A Correa","year":"2007","unstructured":"Correa A, Cragan JD, Kucik JE, Alverson CJ, Gilboa SM, Balakrishnan R, et al. Reporting birth defects surveillance data 1968-2003 [published correction appears in Birth Defects Res A Clin Mol Teratol 2008;82:41-62]. Birth Defects Res A Clin Mol Teratol. 2007;79:65\u2013186.","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"674_CR26","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/146642408710700114","volume":"107","author":"CC Anokute","year":"1987","unstructured":"Anokute CC. Epidemiology of spontaneous abortions\u2014the effect of previous abortions. J R Soc Health. 1987;107:31\u20133.","journal-title":"J R Soc Health"},{"key":"674_CR27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1728-4465.2007.00130.x","volume":"38","author":"RK Jones","year":"2007","unstructured":"Jones RK, Kost K. Underreporting of induced and spontaneous abortion in the United States: an analysis of the 2002 National Survey of Family Growth. Stud Fam Plann. 2007;38:187\u201397.","journal-title":"Stud Fam Plann"},{"key":"674_CR28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/1352458509106543","volume":"15","author":"C Weber-Schoendorfer","year":"2009","unstructured":"Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15:1037\u201342.","journal-title":"Mult Scler"},{"key":"674_CR29","first-page":"1","volume":"64","author":"JA Martin","year":"2015","unstructured":"Martin JA, Hamilton BE, Osterman MJ, Curtin SC, Matthews TJ. Births: final data for 2013. Natl Vital Stat Rep. 2015;64:1\u201365.","journal-title":"Natl Vital Stat Rep"},{"key":"674_CR30","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ydbio.2006.01.026","volume":"293","author":"A Grazioli","year":"2006","unstructured":"Grazioli A, Alves CS, Konstantopoulos K, Yang JT. Defective blood vessel development and pericyte\/pvSMC distribution in alpha 4 integrin-deficient mouse embryos. Dev Biol. 2006;293:165\u201377.","journal-title":"Dev Biol"},{"key":"674_CR31","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1242\/dev.121.2.489","volume":"121","author":"L Kwee","year":"1995","unstructured":"Kwee L, Baldwin HS, Shen HM, Stewart CL, Buck C, Buck CA, et al. Defective development of the embryonic and extraembryonic circulatory systems in vascular cell adhesion molecule (VCAM-1) deficient mice. Development. 1995;121:489\u2013503.","journal-title":"Development"},{"key":"674_CR32","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0015-0282(97)81388-X","volume":"67","author":"K Sueoka","year":"1997","unstructured":"Sueoka K, Shiokawa S, Miyazaki T, Kuji N, Tanaka M, Yoshimura Y. Integrins and reproductive physiology: expression and modulation in fertilization, embryogenesis, and implantation. Fertil Steril. 1997;67:799\u2013811.","journal-title":"Fertil Steril"},{"key":"674_CR33","first-page":"23","volume":"231","author":"N Wagner","year":"1998","unstructured":"Wagner N, M\u00fcller W. Functions of alpha 4- and beta 7-integrins in hematopoiesis, lymphocyte trafficking and organ development. Curr Top Microbiol Immunol. 1998;231:23\u201332.","journal-title":"Curr Top Microbiol Immunol"},{"key":"674_CR34","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1242\/dev.121.2.549","volume":"121","author":"JT Yang","year":"1995","unstructured":"Yang JT, Rayburn H, Hynes RO. Cell adhesion events mediated by alpha 4 integrins are essential in placental and cardiac development. Development. 1995;121:549\u201360.","journal-title":"Development"},{"key":"674_CR35","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1101\/gad.9.15.1896","volume":"9","author":"R F\u00e4ssler","year":"1995","unstructured":"F\u00e4ssler R, Meyer M. Consequences of lack of beta 1 integrin gene expression in mice. Genes Dev. 1995;9:1896\u2013908.","journal-title":"Genes Dev"},{"key":"674_CR36","volume-title":"Pediatric and Pregnancy: Nutrition Surveillance System","author":"Centers for Disease Control and Prevention","year":"2009","unstructured":"Centers for Disease Control and Prevention. Pediatric and Pregnancy: Nutrition Surveillance System. 2009. http:\/\/www.cdc.gov\/pednss\/what_is\/pednss_health_indicators.htm#birthweight . Accessed 30 Apr 2015."},{"key":"674_CR37","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1111\/ane.12222","volume":"129","author":"J Fagius","year":"2014","unstructured":"Fagius J, Burman J. Normal outcome of pregnancy with ongoing treatment with natalizumab. Acta Neurol Scand. 2014;129:e27\u2013e9.","journal-title":"Acta Neurol Scand"},{"key":"674_CR38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","volume":"71","author":"A Haghikia","year":"2014","unstructured":"Haghikia A, Langer-Gould A, Rellensmann G, Schneider H, Tenenbaum T, Elias-Hamp B, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71:891\u20135.","journal-title":"JAMA Neurol"},{"key":"674_CR39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/(SICI)1096-9926(199912)60:6<356::AID-TERA8>3.0.CO;2-B","volume":"60","author":"MA Honein","year":"1999","unstructured":"Honein MA, Paulozzi LJ, Cragan JD, Correa A. Evaluation of selected characteristics of pregnancy drug registries. Teratology. 1999;60:356\u201364.","journal-title":"Teratology"},{"key":"674_CR40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1468-1331.2010.02971.x","volume":"17","author":"JH Kang","year":"2010","unstructured":"Kang JH, Chen YH, Lin HC. Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol. 2010;17:1215\u20139.","journal-title":"Eur J Neurol"},{"key":"674_CR41","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000343188","volume":"40","author":"RA Marrie","year":"2013","unstructured":"Marrie RA, Yu BN, Leung S, Elliott L, Caetano P, Warren S, et al. CIHR Team in the Epidemiology and Impact of Comomrbidity on Multiple Sclerosis. The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology. 2013;40:85\u201392.","journal-title":"Neuroepidemiology"},{"key":"674_CR42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1177\/1352458508096680","volume":"15","author":"R Marrie","year":"2009","unstructured":"Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler. 2009;15:105\u201313.","journal-title":"Mult Scler"},{"key":"674_CR43","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/GCO.0b013e32834cef8f","volume":"23","author":"A Tsui","year":"2011","unstructured":"Tsui A, Lee MA. Multiple sclerosis and pregnancy. Curr Opin Obstet Gynecol. 2011;23:435\u20139.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"674_CR44","doi-asserted-by":"crossref","first-page":"e004536","DOI":"10.1136\/bmjopen-2013-004536","volume":"4","author":"PK Coyle","year":"2014","unstructured":"Coyle PK, Sinclair SM, Scheuerle AE, Thorp Jr JM, Albano JD, Rametta MJ. Final results from the Betaseron (interferon \u03b2-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events. BMJ Open. 2014;4:e004536.","journal-title":"BMJ Open"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0674-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T23:00:52Z","timestamp":1657148452000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0674-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,24]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["674"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0674-4","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,24]]},"article-number":"150"}}